Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Edoardo Biondi, Michelino De Laurentiis et al.|The Lancet Oncology|2018

Cited by 88